Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04717934 · ClinicalTrials.gov registry record · NA

Main Study: A Study to Evaluate the Effectiveness and Safety of GAL1906 for Correction of Wrinkles in the décolletage Area Sub-study: A Follow-up Study to Evaluate the Analysis of Mammograms Following Treatment for Correction of Wrinkles in Décolletage Area in the Investigational Study 43USRV1906

A NA study, sponsored by Galderma R&D.

Completed
Registry status
NA
Development phase
211
Enrollment target

NCT04717934: Completed NA study, sponsored by Galderma R&D.

NCT04717934 is a NA study that has completed, run by Galderma R&D. The registered enrollment target is 211 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04717934, a NA study, has completed, sponsored by Galderma R&D.

COMPLETED
Registry status
NA
Development phase
211 participants
Enrollment target

Study Summary

Main study: Randomized, evaluator-blinded, no treatment controlled multicenter study to evaluate safety and effectiveness of GAL1906 for the correction of wrinkles in the décolletage area. Sub-study: To evaluate imaging interpretation of mammograms in subjects who were enrolled and treated in the 43USRV1906 main study. The sub-study will determine if hyaluronic acid injections in the décolletage interfere with diagnosis or interpretation of mammogram results.

Primary Outcome

Responder was defined as participants having at least one grade improvement from baseline on the Galderma decolletage scale. Galderma Decolletage Scale was a validated 5-point scale used to assess the severity of lines and wrinkles in the décolletage area where: Grade 0 (none to minimal), Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (very severe). Higher scores indicated more severe lines and wrinkles in the décolletage area. Percentage of responders as assessed live by the blin

Interventions

  • DEVICE GAL1906

Trial Details

FieldValue
Enrollment Target 211 participants
Start Date 2025-02-11
Est. Completion 2025-06-13
Phase NA
Galderma R&D

158 total trials

What the finished NCT04717934 record still lists

NCT04717934 is an interventional study that assigns participants to a tested intervention. The registered 211 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower).

The record links to 0 conditions, and to 1 intervention - of which GAL1906 is the first listed.

NCT04717934 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04717934 about?

NCT04717934 is a clinical study titled "Main Study: A Study to Evaluate the Effectiveness and Safety of GAL1906 for Correction of Wrinkles in the décolletage Area Sub-study: A Follow-up Study to Evaluate the Analysis of Mammograms Following Treatment for Correction of Wrinkles in Décolletage Area in the Investigational Study 43USRV1906". Main study: Randomized, evaluator-blinded, no treatment controlled multicenter study to evaluate safety and effectiveness of GAL1906 for the correction of wrinkles in the décolletage area. Sub-study: To evaluate imaging interpretation of mammograms in subjects who were enrolled and treated in the 4...

What is the current status of trial NCT04717934?

This trial is currently completed. It is a NA study. The enrollment target is 211 participants. The study started on 2025-02-11. Estimated completion is 2025-06-13.

What interventions are being tested in trial NCT04717934?

The interventions under investigation include: GAL1906 (DEVICE).

Who is sponsoring clinical trial NCT04717934?

This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04717934's enrollment target sits among peer trials

211 490th of 2000 higher than 1,511 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06698796 · 211 participants · Phase 3

    A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

  • NCT04228978 · 212 participants · NA

    Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss

  • NCT04725721 · 212 participants · NA

    Testing FIRST in Youth Outpatient Psychotherapy

  • NCT06257576 · 212 participants · Phase 3

    Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04717934, the US trial registry maintained by the National Library of Medicine. NCT04717934 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.